Abstract
Background Ischemic heart disease (IHD) has the highest mortality rate in the globe. This returns to the poor diagnostic and therapeutic strategies including the early prevention methods.
Aims To assess the changes in the single channel electrocardiography (SCECG) at rest and on exercise test in patients with vs without IHD confirmed by stress computed tomography myocardial perfusion (CTP) imaging with vasodilatation stress-test.
Objectives IHD frequently have preventable risk factors and causes that lead to the disease appearance. However, the lack of the proper diagnostic and prevention tools remains a global challenge in or era despite the current scientific advances.
Material and methods A single center observational study included 38 participants from Moscow. The participants aged ≥ 40 years and given a written consent to participate in the study. Both groups, G1=19 with vs G2=19 without post stress induced myocardial perfusion defect, passed consultation by cardiologist, anthropometric measurements, blood pressure and pulse rate, echocardiography, cardio-ankle vascular index, performing bicycle ergometry, recording 3-minutes SCECG (using CARDO-QVARK ) before and just after bicycle ergometry, and then performing CTP. The LASSO regression with nested cross-validation was used to find association between CARDO-QVARK parameters and the existence of the perfusion defect. Statistical processing carried out using the R programming language v4.2 and Python v.3.10 [^R].
Results The CARDO-QVARK parameters analysis have a specificity 63.2 % [95 % confidence interval (CI); 0.391 ; 0.833], sensitivity 73.7 % [95 % CI ; 0.533 ; 0.929], area under the curve (AUC) 68.4 % [95 % CI ; 0.527 ; 0.817] in compare to bicycle ergometry (AUC; 55.3 %), based on our study results.
Conclusion The SCECG have significantly higher diagnostic accuracy in compare to bicycle ergometry. CARDO-QVARK has the potential to improve the diagnostic accuracy of the bicycle ergometry.
Other Further investigations required to uncover the hidden capabilities of CARDO-QVARK in the diagnosis of ischemic heart disease.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT06181799
Funding Statement
The work financed by the Ministry of Science and Higher Education of the Russian Federation within the framework of state support for the creation and development of World-Class Research Center Digital biodesign and personalized healthcare № 075-15-2022-304
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
the study approved by the Sechenov University, Russia, from Ethics Committee Requirement № 19-23 from 26.10.2023.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Improving the text of the paper
Data Availability
All data produced in the present study are available upon reasonable request to the authors
